Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

Inclusion Criteria

• •At least 18 years of age
• •ECOG PS 0-2
• •Diagnosis of pathologically confirmed stage IV urothelial cancer, regardless of PD-L1 status
• •Patients treated with platinum-based chemotherapy (Cisplatin or Carboplatin) in the first-line setting who have not shown disease progression after 4-6 cycles of chemotherapy
• •Patients receiving Avelumab as maintenance therapy in the first-line setting or Pembrolizumab in the second-line setting
• •Availability of hospital and/or outpatient medical records for clinical data collection
• •Ability to understand and willingness to provide informed consent, or deceased patients at the time of enrollment, in compliance with Article 110 of the Privacy Code and the safeguards established by the Data Protection Authority in Provision No. 298 of May 9, 2024.